BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

405 related articles for article (PubMed ID: 27048531)

  • 1. Different diagnostic values of imaging parameters to predict pseudoprogression in glioblastoma subgroups stratified by MGMT promoter methylation.
    Yoon RG; Kim HS; Paik W; Shim WH; Kim SJ; Kim JH
    Eur Radiol; 2017 Jan; 27(1):255-266. PubMed ID: 27048531
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Choi HJ; Choi SH; You SH; Yoo RE; Kang KM; Yun TJ; Kim JH; Sohn CH; Park CK; Park SH
    AJNR Am J Neuroradiol; 2021 May; 42(5):853-860. PubMed ID: 33632732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Initial Area Under the Curve Derived from Dynamic Contrast-Enhanced MRI Improves Prognosis Prediction in Glioblastoma with Unmethylated
    Choi YS; Ahn SS; Lee HJ; Chang JH; Kang SG; Kim EH; Kim SH; Lee SK
    AJNR Am J Neuroradiol; 2017 Aug; 38(8):1528-1535. PubMed ID: 28642265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discriminating MGMT promoter methylation status in patients with glioblastoma employing amide proton transfer-weighted MRI metrics.
    Jiang S; Rui Q; Wang Y; Heo HY; Zou T; Yu H; Zhang Y; Wang X; Du Y; Wen X; Chen F; Wang J; Eberhart CG; Zhou J; Wen Z
    Eur Radiol; 2018 May; 28(5):2115-2123. PubMed ID: 29234914
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural and advanced imaging in predicting MGMT promoter methylation of primary glioblastoma: a region of interest based analysis.
    Han Y; Yan LF; Wang XB; Sun YZ; Zhang X; Liu ZC; Nan HY; Hu YC; Yang Y; Zhang J; Yu Y; Sun Q; Tian Q; Hu B; Xiao G; Wang W; Cui GB
    BMC Cancer; 2018 Feb; 18(1):215. PubMed ID: 29467012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic dilemma of pseudoprogression in the treatment of newly diagnosed glioblastomas: the role of assessing relative cerebral blood flow volume and oxygen-6-methylguanine-DNA methyltransferase promoter methylation status.
    Kong DS; Kim ST; Kim EH; Lim DH; Kim WS; Suh YL; Lee JI; Park K; Kim JH; Nam DH
    AJNR Am J Neuroradiol; 2011 Feb; 32(2):382-7. PubMed ID: 21252041
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incremental Prognostic Value of ADC Histogram Analysis over MGMT Promoter Methylation Status in Patients with Glioblastoma.
    Choi YS; Ahn SS; Kim DW; Chang JH; Kang SG; Kim EH; Kim SH; Rim TH; Lee SK
    Radiology; 2016 Oct; 281(1):175-84. PubMed ID: 27120357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting MGMT Promoter Methylation of Glioblastoma from Dynamic Susceptibility Contrast Perfusion: A Radiomic Approach.
    Crisi G; Filice S
    J Neuroimaging; 2020 Jul; 30(4):458-462. PubMed ID: 32374045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnosis of pseudoprogression using MRI perfusion in patients with glioblastoma multiforme may predict improved survival.
    Gahramanov S; Varallyay C; Tyson RM; Lacy C; Fu R; Netto JP; Nasseri M; White T; Woltjer RL; Gultekin SH; Neuwelt EA
    CNS Oncol; 2014 Nov; 3(6):389-400. PubMed ID: 25438810
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiregional radiomics features from multiparametric MRI for prediction of MGMT methylation status in glioblastoma multiforme: A multicentre study.
    Li ZC; Bai H; Sun Q; Li Q; Liu L; Zou Y; Chen Y; Liang C; Zheng H
    Eur Radiol; 2018 Sep; 28(9):3640-3650. PubMed ID: 29564594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined analysis of MGMT methylation and dynamic-susceptibility-contrast MRI for the distinction between early and pseudo-progression in glioblastoma patients.
    Bani-Sadr A; Berner LP; Barritault M; Chamard L; Bidet CM; Eker OF; Hermier M; Guyotat J; Jouanneau E; Meyronet D; Gouttard S; D'Hombres A; Iziquierdo C; Honnorat J; Berthezène Y; Ducray F
    Rev Neurol (Paris); 2019 Oct; 175(9):534-543. PubMed ID: 31208813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apparent diffusion coefficient obtained by magnetic resonance imaging as a prognostic marker in glioblastomas: correlation with MGMT promoter methylation status.
    Romano A; Calabria LF; Tavanti F; Minniti G; Rossi-Espagnet MC; Coppola V; Pugliese S; Guida D; Francione G; Colonnese C; Fantozzi LM; Bozzao A
    Eur Radiol; 2013 Feb; 23(2):513-20. PubMed ID: 22875158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Arterial spin labeling perfusion-weighted imaging aids in prediction of molecular biomarkers and survival in glioblastomas.
    Yoo RE; Yun TJ; Hwang I; Hong EK; Kang KM; Choi SH; Park CK; Won JK; Kim JH; Sohn CH
    Eur Radiol; 2020 Feb; 30(2):1202-1211. PubMed ID: 31468161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation of apparent diffusion coefficient values measured by diffusion MRI and MGMT promoter methylation semiquantitatively analyzed with MS-MLPA in patients with glioblastoma multiforme.
    Sunwoo L; Choi SH; Park CK; Kim JW; Yi KS; Lee WJ; Yoon TJ; Song SW; Kim JE; Kim JY; Kim TM; Lee SH; Kim JH; Sohn CH; Park SH; Kim IH; Chang KH
    J Magn Reson Imaging; 2013 Feb; 37(2):351-8. PubMed ID: 23023975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients.
    Brandes AA; Franceschi E; Tosoni A; Blatt V; Pession A; Tallini G; Bertorelle R; Bartolini S; Calbucci F; Andreoli A; Frezza G; Leonardi M; Spagnolli F; Ermani M
    J Clin Oncol; 2008 May; 26(13):2192-7. PubMed ID: 18445844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiomics signature: A potential biomarker for the prediction of MGMT promoter methylation in glioblastoma.
    Xi YB; Guo F; Xu ZL; Li C; Wei W; Tian P; Liu TT; Liu L; Chen G; Ye J; Cheng G; Cui LB; Zhang HJ; Qin W; Yin H
    J Magn Reson Imaging; 2018 May; 47(5):1380-1387. PubMed ID: 28926163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multi-sequence and habitat-based MRI radiomics signature for preoperative prediction of MGMT promoter methylation in astrocytomas with prognostic implication.
    Wei J; Yang G; Hao X; Gu D; Tan Y; Wang X; Dong D; Zhang S; Wang L; Zhang H; Tian J
    Eur Radiol; 2019 Feb; 29(2):877-888. PubMed ID: 30039219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MRI texture features as biomarkers to predict MGMT methylation status in glioblastomas.
    Korfiatis P; Kline TL; Coufalova L; Lachance DH; Parney IF; Carter RE; Buckner JC; Erickson BJ
    Med Phys; 2016 Jun; 43(6):2835-2844. PubMed ID: 27277032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinically Relevant Imaging Features for
    Suh CH; Kim HS; Jung SC; Choi CG; Kim SJ
    AJNR Am J Neuroradiol; 2018 Aug; 39(8):1439-1445. PubMed ID: 30002055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IDH mutation and MGMT promoter methylation are associated with the pseudoprogression and improved prognosis of glioblastoma multiforme patients who have undergone concurrent and adjuvant temozolomide-based chemoradiotherapy.
    Li H; Li J; Cheng G; Zhang J; Li X
    Clin Neurol Neurosurg; 2016 Dec; 151():31-36. PubMed ID: 27764705
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.